RAFAEL HOLDINGS INC-CLASS B (RFL) Stock News

USA - NYSE:RFL - US75062E1064 - Common Stock

1.22 USD

-0.04 (-3.17%)

Last: 11/14/2025, 8:22:59 PM

1.2 USD

-0.02 (-1.64%)

After Hours: 11/14/2025, 8:22:59 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RFL Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

18 days ago - By: Rafael Holdings, Inc.

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

18 days ago - By: Benzinga - Mentions: IVA AVTR GNTA AKBA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

19 days ago - By: Rafael Holdings, Inc.

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

19 days ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

a month ago - By: Benzinga - Mentions: OMI XTLB ESPR PCSA ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

2 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

3 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

3 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

5 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

5 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

5 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

5 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

5 months ago - By: Rafael Holdings, Inc.

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

5 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

6 months ago - By: Rafael Holdings, Inc.

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of

6 months ago - By: Rafael Holdings, Inc. - Mentions: NYSE

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of

7 months ago - By: Rafael Holdings, Inc.

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

7 months ago - By: Rafael Holdings, Inc.

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

7 months ago - By: Rafael Holdings, Inc.

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

7 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

7 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

8 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

8 months ago - By: Rafael Holdings, Inc. - Mentions: CYTH

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

8 months ago - By: Rafael Holdings, Inc. - Mentions: CYTH

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

8 months ago - By: Rafael Holdings, Inc.

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results